MassIVE MSV000096381

Partial Public

Uncovering New Biomarkers for Prostate Cancer Through Proteomic and Network analysis

Description

Two hundred microliters per protein sample, collected at the end of isolation, were concentrated to 50 microL in a vacuum concentrator at 60C and treated with RapiGestTMSF reagent (Waters Co, Milford, MA, USA) at the final concentration of 0.25% (w/v). The resulting suspensions were incubated under stirring at 100C for 20 minutes. Subsequently the samples were cooled to room temperature and centrifuged 10 min at 2200 g. The protein concentration was assayed using the Invitrogen Qubit Protein BR Assay Kit (Life Technologies Corporation, Thermo Fisher, Eugene, ORE, USA) and 50 microg proteins from each sample were digested overnight at 37C by adding Sequencing grade Modified Trypsin (Promega Inc., Madison, WI, USA) at an enzyme substrate ratio of 1:50 (w/w) in 0.1M NH4HCO3 pH 7.9 buffer with 10% CH3CN. An additional aliquot of trypsin (1:100 w/w) was then added the next day, and the digestion continued for 4h. The enzymatic digestion was chemically stopped by acidification with 0.5%Trifluoroacetic Acid (TFA) (SigmaAldrich Inc., St. Louis, MO, USA), and a subsequent incubation at 37C for 45 minutes completed the RapiGest acid hydrolysis. Water immiscible degradation products were removed by centrifugation at 13,000 rpm for 10 minutes. Finally, the tryptic digest mixtures were desalted using PierceTM C 18 spin columns (Thermo Fisher Scientific,Pierce Biotechnology, Rockford, Il, USA), according to manufacturer protocol and were resuspended in 0.1% formic acid (Sigma-Aldrich Inc., St. Louis, MO, USA) in water (LC MS Ultra CHROMASOLV, Honeywell Riedelde HaenTM, Muskegon, MI, USA) at a concentration of 0.1 microg/microL. The nanoLC MS/MS experiments were performed using the LTQ Orbitrap XL ETD mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) coupled with Eksigen nanoLC-Ultra 2D System (Eksigent, part of AB SCIEX Dublin, CA, USA) configured I trap elute mode. Briefly, samples (0.8microg injected) were first loaded on a trap (200 microm x 500 microm ChromXP C18 CL, 3 microm, 120 A) and washed with the loading pump running in isocratic mode with 0.1% formic acid in water for 10 minutes at a flow of 3 microL/min. The automatic switching of auto-sampler ten-port valve then eluted the trapped mixture on a nano reversed phase column (75 microm x 15 cm ChromXP C18 CL, 3 microm, 120 A) through a 130 minutes gradient of eluent B (eluent A, 0.1% formic acid in water; eluent B, 0.1% formic acid in acetonitrile) at a flow rate of 300 nL/min. In depth, gradient was: from 5 10% B in 5 min, 10 40% B in 85min, 40 95% B in 27 min and holding at 95% B for 10 min. The eluated peptides were directly analyzed into a LTQ Orbitrap XL ETD through a nano electrospray ion source (Thermo Fisher Scientific); each sample was analyzed in at least 3 technical replicates. The spray capillary voltage was set at 1.7 kV and the ion transfer capillary temperature was held at 220C. Full MS spectra were recorded over a 400 1600 m/z range in positive ion mode, with a resolving power of 30000 (full width at half-maximum) and a scan rate of 2 spectra/s. This step was followed by 5 low resolution MS/MS events that were sequentially generated in a data-dependent manner on the top five ions selected from the full MS spectrum (at 35% collision energy), using dynamic exclusion of 0.5 min for MS/MS analysis. Mass spectrometer scan functions and high-performance liquid chromatography solvent gradients were controlled by the Xcalibur data system version 1.4 (Thermo Fisher Scientific, MA, USA). File description: HD > Healthy donors LRPCa > low risk patients (bladder cancer) HRPCa > high risk patients (bladder cancer) Sub > subject I, II, III etc...> technical replicates [doi:10.25345/C5V698Q4D] [dataset license: CC0 1.0 Universal (CC0 1.0)]

Keywords: Urine ; Prostate cancer ; DatasetType:Proteomics

Contact

Principal Investigators:
(in alphabetical order)
Dario Di Silvestre, Institute of Biomedical Technologies, Italy
Pierluigi Mauri, Institute of Biomedical Technologies, Italy
Rossana Rossi, Institute of Biomedical Technologies, Italy
Submitting User: Dds100
Number of Files:
Total Size:
Spectra:
Subscribers:
 
Owner Reanalyses
Experimental Design
    Conditions:
    Biological Replicates:
    Technical Replicates:
 
Identification Results
    Proteins (Human, Remapped):
    Proteins (Reported):
    Peptides:
    Variant Peptides:
    PSMs:
 
Quantification Results
    Differential Proteins:
    Quantified Proteins:
 
Browse Dataset Files
 
FTP Download Link (click to copy):

- Dataset Reanalyses


+ Dataset History


Click here to queue conversion of this dataset's submitted spectrum files to open formats (e.g. mzML). This process may take some time.

When complete, the converted files will be available in the "ccms_peak" subdirectory of the dataset's FTP space (accessible via the "FTP Download" link to the right).
Number of distinct conditions across all analyses (original submission and reanalyses) associated with this dataset.

Distinct condition labels are counted across all files submitted in the "Metadata" category having a "Condition" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct biological replicates across all analyses (original submission and reanalyses) associated with this dataset.

Distinct replicate labels are counted across all files submitted in the "Metadata" category having a "BioReplicate" or "Replicate" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct technical replicates across all analyses (original submission and reanalyses) associated with this dataset.

The technical replicate count is defined as the maximum number of times any one distinct combination of condition and biological replicate was analyzed across all files submitted in the "Metadata" category. In the case of fractionated experiments, only the first fraction is considered.

"N/A" means no results of this type were submitted.
Originally identified proteins that were automatically remapped by MassIVE to proteins in the SwissProt human reference database.

"N/A" means no results of this type were submitted.
Number of distinct protein accessions reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct unmodified peptide sequences reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct peptide sequences (including modified variants or peptidoforms) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Total number of peptide-spectrum matches (i.e. spectrum identifications) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins quantified across all analyses (original submission and reanalyses) associated with this dataset.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins found to be differentially abundant in at least one comparison across all analyses (original submission and reanalyses) associated with this dataset.

A protein is differentially abundant if its change in abundance across conditions is found to be statistically significant with an adjusted p-value <= 0.05 and lists no issues associated with statistical tests for differential abundance.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
This dataset may not contain all raw spectra data as originally deposited in PRIDE. It has been imported to MassIVE for reanalysis purposes, so its spectra data here may consist solely of processed peak lists suitable for reanalysis with most software.